Voss Capital, LLC In8 Bio, Inc. Transaction History

Voss Capital, LLC

$1.05 Billion
Q3 2024

A detailed history of Voss Capital, LLC transactions in In8 Bio, Inc. stock. As of the latest transaction made, Voss Capital, LLC holds 64,000 shares of INAB stock, worth $16,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

64,000

Previous 91,000 29.67%

Holding current value

$16,000

Previous $77,000 77.92%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$0.27 - $0.88 $7,290 - $23,760	-27,000 Reduced 29.67%	64,000 $17,000
Q2 2024 Aug 14, 2024	SELL	$0.85 - $1.68 $197,607 - $390,564	-232,479 Reduced 71.87%	91,000 $77,000
Q1 2024 May 14, 2024	SELL	$0.95 - $1.69 $16,843 - $29,963	-17,730 Reduced 5.2%	323,479 $381,000
Q4 2023 Jan 30, 2024	SELL	$0.69 - $2.34 $117,558 - $398,677	-170,375 Reduced 33.3%	341,209 $470,000
Q3 2023 Oct 19, 2023	BUY	$0.92 - $1.74 $49,411 - $93,451	53,708 Added 11.73%	511,584 $532,000
Q2 2023 Jul 28, 2023	BUY	$1.05 - $3.24 $125,849 - $388,336	119,857 Added 35.46%	457,876 $705,000
Q4 2022 Feb 13, 2023	SELL	$1.39 - $2.47 $52,195 - $92,750	-37,551 Reduced 10.0%	338,019 $780,000
Q3 2022 Nov 02, 2022	SELL	$1.77 - $2.89 $230,215 - $375,887	-130,065 Reduced 25.72%	375,570 $759,000
Q2 2022 Aug 09, 2022	BUY	$2.02 - $4.68 $498,196 - $1.15 Million	246,632 Added 95.22%	505,635 $1.14 Million
Q1 2022 May 13, 2022	BUY	$2.76 - $4.6 $433,938 - $723,230	157,224 Added 154.48%	259,003 $875,000
Q4 2021 Feb 14, 2022	BUY	$4.39 - $8.55 $92,418 - $179,994	21,052 Added 26.08%	101,779 $446,000
Q3 2021 Nov 16, 2021	BUY	$6.71 - $10.0 $541,678 - $807,270	80,727 New	80,727 $555,000

Others Institutions Holding INAB

# of Institutions

Shares Held

7.62M

Call Options Held

Put Options Held

View Full List

About IN8BIO, INC.

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $6.13M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

More about INAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Voss Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voss Capital, LLC with notifications on news.

Account